Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening

被引:16
作者
Deng, Ling [1 ]
Yang, Li [2 ]
Zhu, Shuhan [1 ]
Li, Man [1 ]
Wang, Yu [1 ]
Cao, Xiaolong [3 ,4 ]
Wang, Qiongyao [5 ]
Guo, Linlang [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Pathol, Guangzhou, Peoples R China
[2] Univ Hong Kong, Shenzhen Hosp, Clin Oncol Ctr, Shenzhen, Peoples R China
[3] Southern Med Univ, Zhujiang Hosp, Div Lab Med, Guangzhou, Peoples R China
[4] Southern Med Univ, Zhujiang Hosp, Translat Med Res Ctr, Guangzhou, Peoples R China
[5] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
GENETIC SCREENS; TRILACICLIB; RECURRENT;
D O I
10.1038/s41420-023-01315-2
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
There is currently a lack of efficacious treatments for patients with chemo-resistant small-cell lung cancer (SCLC), leading to poor prognoses. We examined a chemo-resistant SCLC cell line using genome-wide CRISPR/Cas9 screening and identified serine/threonine kinase cell division cycle 7 (CDC7) as a potential synergistic target. Silencing CDC7 in chemo-resistant SCLC cells decreased the IC50 and improved the efficacy of chemotherapy. Based on the highest single agent model, the CDC7 inhibitor XL413 had a synergistic effect with both cisplatin and etoposide in chemo-resistant SCLC cells, but had no such effect in chemo-sensitive SCLC cells; the combination of XL413 and chemotherapy significantly inhibited cell growth. Western blot and flow cytometry showed that the combined treatments increased apoptosis, whereas XL413 alone had little effect on apoptosis. An analysis of cell cycle and cyclin protein levels indicated that the combination of XL413 and chemotherapy-induced G1/S phase arrest and DNA damage in chemo-resistant SCLC cells. Xenografted tumor and histoculture drug response assays using patient-derived xenografts showed that XL413 improved the efficacy of chemotherapy in vivo and with SCLC tissues. These results suggest that XL413 exerts a synergistic effect with chemotherapy on chemo-resistant SCLC.
引用
收藏
页数:10
相关论文
共 36 条
[1]   CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway [J].
Chen, Jiang ;
Jiang, Shi ;
Shao, Huijiang ;
Li, Bixia ;
Ji, Tong ;
Staiculescu, Daniel ;
He, Jiayan ;
Zhao, Jie ;
Cai, Liuxin ;
Liang, Xiao ;
Xu, Junjie ;
Cai, Xiujun .
SCIENCE CHINA-LIFE SCIENCES, 2022, 65 (10) :1998-2016
[2]   Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies [J].
Chung, Hyun Cheol ;
Piha-Paul, Sarina A. ;
Lopez-Martin, Jose ;
Schellens, Jan H. M. ;
Kao, Steven ;
Miller, Wilson H., Jr. ;
Delord, Jean-Pierre ;
Gao, Bo ;
Planchard, David ;
Gottfried, Maya ;
Zer, Alona ;
Jalal, Shadia I. ;
Penel, Nicolas ;
Mehnert, Janice M. ;
Matos, Ignacio ;
Bennouna, Jaafar ;
Kim, Dong-Wan ;
Xu, Lei ;
Krishnan, Suba ;
Norwood, Kevin ;
Ott, Patrick A. .
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) :618-627
[3]   Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway [J].
Gad, Shaimaa A. ;
Ali, Hamdy E. A. ;
Gaballa, Rofaida ;
Abdelsalam, Rania M. ;
Zerfaoui, Mourad ;
Ali, Hamed I. ;
Salama, Salwa H. ;
Kenawy, Sanaa A. ;
Kandil, Emad ;
Abd Elmageed, Zakaria Y. .
SCIENTIFIC REPORTS, 2019, 9 (1)
[4]   Structural mechanism for the selective phosphorylation of DNA-loaded MCM double hexamers by the Dbf4-dependent kinase [J].
Greiwe, Julia F. ;
Miller, Thomas C. R. ;
Locke, Julia ;
Martino, Fabrizio ;
Howell, Steven ;
Schreiber, Anne ;
Nans, Andrea ;
Diffley, John F. X. ;
Costa, Alessandro .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2022, 29 (01) :10-+
[5]   Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer [J].
Guo, Yuchen ;
Wang, Jun ;
Benedict, Bente ;
Yang, Chen ;
van Gemert, Frank ;
Ma, Xuhui ;
Gao, Dongmei ;
Wang, Hui ;
Zhang, Shu ;
Lieftink, Cor ;
Beijersbergen, Roderick L. ;
Te Riele, Hein ;
Qiao, Xiaohang ;
Gao, Qiang ;
Sun, Chong ;
Qin, Wenxin ;
Bernards, Rene ;
Wang, Cun .
GENOME MEDICINE, 2021, 13 (01)
[6]   Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma [J].
Huang, Shanzhou ;
Ma, Zuyi ;
Zhou, Qi ;
Wang, Aimei ;
Gong, Yuanfeng ;
Li, Zhenchong ;
Wang, Shujie ;
Yan, Qian ;
Wang, Dongping ;
Hou, Baohua ;
Zhang, Chuanzhao .
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2022, 18 (11) :4357-4371
[7]   Circular RNA cESRP1 sensitises small cell lung cancer cells to chemotherapy by sponging miR-93-5p to inhibit TGF-β signalling [J].
Huang, Weimei ;
Yang, Yunchu ;
Wu, Jingfang ;
Niu, Yuchun ;
Yao, Yao ;
Zhang, Jian ;
Huang, Xiaoxian ;
Liang, Shumei ;
Chen, Rui ;
Chen, Size ;
Guo, Linlang .
CELL DEATH AND DIFFERENTIATION, 2020, 27 (05) :1709-1727
[8]   POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer [J].
Huang, Yu-Han ;
Klingbeil, Olaf ;
He, Xue-Yan ;
Wu, Xiaoli S. ;
Arun, Gayatri ;
Lu, Bin ;
Somerville, Tim D. D. ;
Milazzo, Joseph P. ;
Wilkinson, John E. ;
Demerdash, Osama E. ;
Spector, David L. ;
Egeblad, Mikala ;
Shi, Junwei ;
Vakoc, Christopher R. .
GENES & DEVELOPMENT, 2018, 32 (13-14) :915-928
[9]   Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies [J].
Hussein, Maen ;
Maglakelidze, Marina ;
Richards, Donald A. ;
Sabatini, Marielle ;
Gersten, Todd A. ;
Lerro, Keith ;
Sinielnikov, Ivan ;
Spira, Alexander ;
Pritchett, Yili ;
Malik, Rajesh ;
Beck, J. Thaddeus .
CANCER MANAGEMENT AND RESEARCH, 2021, 13 :6207-6218
[10]  
Ianevski A., 2020, NUCLEIC ACIDS RES, V48, pW488, DOI [DOI 10.1093/NAR/GKAA216, 10.1093/nar/gkaa216]